$13 Mln
$-25 Mln
--
As on 22-Sep-2023 16:00 EDT
$-0.05
•
-1.28%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Landos Biopharma (LABP)
| -23.00 | 1.05 | 8.15 | -51.27 | -- | -- | -- |
|
S&P BSE Sensex
| 8.49 | 1.22 | 3.91 | 11.02 | 20.17 | 12.37 | 12.54 |
|
S&P Small-Cap 600#
| -0.96 | -4.96 | -1.70 | 6.06 | 11.70 | 1.31 | 6.60 |
|
2022
|
|
|---|---|
|
Landos Biopharma (LABP)
| -89.58 |
|
S&P Small-Cap 600
| -17.42 |
|
S&P BSE Sensex
| 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Landos Biopharma Inc. (LABP) stood at $ 55 Mln as on 31-Mar-23
The share price of Landos Biopharma Inc. (LABP) is $3.850000 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Landos Biopharma Inc. (LABP) has given a return of -51.27% in the last 1 years.
Landos Biopharma Inc. (LABP) has a market capitalisation of $ 13 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Landos Biopharma Inc. (LABP) is 0.24 times as on 09-Jun-2023, a -0.91% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Landos Biopharma Inc. (LABP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Landos Biopharma Inc. (LABP) and enter the required number of quantities and click on buy to purchase the shares of Landos Biopharma Inc. (LABP).
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
The CEO & director of Mr. Timothy M. Mayleben M.B.A.. is Landos Biopharma Inc. (LABP), and CFO & Sr. VP is Dr. Josep Bassaganya-Riera DVM, Ph.D..
The promoters of Landos Biopharma Inc. (LABP) have pledged 0% of the total equity as on Mar-23.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
524
|
|
|
377
|
|
|
365
|
|
|
330
|
| Landos Biopharma Inc. (LABP) | Ratios |
|---|---|
|
Return on equity(%)
|
-63.13
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Landos Biopharma Inc. (LABP) was $-25 Mln.
$12.67 Mln
$0.00 Mln
$-25.21 Mln
$50.01 Mln
$0.00 Mln
Moderate
$2.11 - 7.57
3,116,840
NASDAQ: LABP
Blacksburg, VA
https://landosbiopharma.com
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1),... a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
